主动脉腔内器械试验中性别、种族和民族报告与代表性的差异
该研究检索美国FDA医疗器械数据库1999年9月至2021年11月批准的29项主动脉腔内器械关键试验(共4046例患者),分析性别、种族和民族的报告率与入组比例。结果显示女性在EVAR试验中入组比例最低(中位数11%),种族和民族 minority 群体报告不足且代表性低;作者建议标准化报告实践并设定少数群体和女性参与的最低阈值。
要点
- 29项试验均报告性别,女性入组中位数21%(IQR 11%-34%)。
- EVAR试验女性入组最低(11%),TEVAR为41%(P < .01)。
- 仅52%试验报告三大种族,48%报告西班牙裔;EVAR报告率最低。
核心结论
- 导致FDA批准的主动脉器械关键试验中,种族和民族 minority 群体代表性不足且报告不足;女性患者在这些主动脉试验中同样代表性不足,尤其是EVAR。
- 这些数据提示需要标准化报告实践并设定关键试验中少数群体和女性参与的最低阈值,以促进公平代表性。
研究设计与样本
- 查询FDA医疗器械数据库,纳入1999年9月至2021年11月所有FDA批准的用于治疗主动脉瘤、横断和夹层的腔内移植物,包括EVAR、TEVAR、FEVAR器械和夹层支架;扩大适应证的多次批准单独纳入。
- 共29项试验的29项批准,涉及24种器械:15种EVAR器械(52%)、12种TEVAR器械(41%)、1种FEVAR器械(3.4%)、1种夹层支架(3.4%);试验共纳入4046例患者。
主要发现
- 29项试验均报告参与者性别,女性入组中位数为21%(IQR 11%-34%)。
- EVAR试验女性入组最低(11%;IQR 8.7%-13%),TEVAR为41%(IQR 27%-45%),FEVAR为21%,夹层支架为34%(差异P < .01)。
- 仅52%的试验报告了三个最常见种族(白人、黑人、亚裔),仅48%报告了西班牙裔 ethnicity。
- TEVAR试验最可能报告所有三个种族和西班牙裔 ethnicity(分别为92%和75%),EVAR试验报告率最低(分别为13%和20%)。
- 在有报告的情况下,各试验中种族和 ethnic 群体入组中位数:黑人患者9.8%(FEVAR 0%;EVAR 1.9%;TEVAR 12%;夹层支架25%;P = .01);亚裔患者2.4%(EVAR 0.6%;FEVAR 2.4%;TEVAR 2.5%;夹层支架11%;P = .24);西班牙裔患者3.8%(EVAR 1.3%;FEVAR 2.4%;TEVAR 3.9%;夹层支架4.1%;P = .75)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Vulnerable populations, including women and racial and ethnic minorities, have been historically underrepresented in clinical trials. We, therefore, studied the demographics of patients enrolled in pivotal endovascular aortic device trials in the United States. METHODS: We queried the Food and Drug Administration (FDA) medical devices database for all FDA-approved endografts for the treatment of aortic aneurysms, transections, and dissections from September 1999 to November 2021. These included abdominal endovascular aortic repair (EVAR), thoracic EVAR (TEVAR), fenestrated EVAR (FEVAR) devices, and dissection stents. Multiple cases of approval for expanded indications were included separately. The primary outcomes included the proportion of trials reporting participant sex, race, and ethnicity and the proportion of enrolled participants across sex, racial, and ethnic groups. RESULTS: The FDA provided 29 approvals from 29 trials of 24 devices: 15 EVAR devices (52%), 12 TEVAR devices (41%), 1 FEVAR device (3.4%), and 1 dissection stent (3.4%). These trials had included 4046 patients. Of the 29 trials, all had reported on the sex of the participants, and the median female enrollment was 21% (interquartile range [IQR], 11%-34%). The EVAR trials had the lowest female enrollment (11%; IQR, 8.7%-13%) compared with 41% (IQR, 27%-45%) in the TEVAR trials, 21% in the FEVAR trial, and 34% in the dissection stent trial (P < .01 for the difference). Only 52% of the trials had reported the three most common racial groups (White, Black, Asian), and only 48% had reported Hispanic ethnicity. The TEVAR trials were the most likely to report all three racial groups and Hispanic ethnicity (92% and 75%, respectively), while the EVAR trials had the lowest reporting rates (13% and 20%, respectively). Where reported, the median enrollment of racial and ethnic groups across the trials was as follows: Black patients, 9.8% (FEVAR, 0%; EVAR, 1.9%; TEVAR, 12%; dissection stent, 25%; P = .01); Asian patients, 2.4% (EVAR, 0.6%; FEVAR, 2.4%; TEVAR, 2.5%; dissection stent, 11%; P = .24); and Hispanic patients, 3.8% (EVAR, 1.3%; FEVAR, 2.4%; TEVAR, 3.9%; dissection stent, 4.1%; P = .75). CONCLUSIONS: Racial and ethnic minority groups were underrepresented and underreported in pivotal aortic device trials that led to FDA approval. Female patients were also underrepresented in these aortic trials, especially for EVAR. These data suggest the need for standardization of reporting practices and minimum thresholds for minority and female participation in pivotal trials to promote equitable representation.
引用
- Marcaccio CL, O'Donnell TFX, Dansey KD, et al. Disparities in reporting and representation by sex, race, and ethnicity in endovascular aortic device trials. J Vasc Surg. 2022. PMID: 35623599. doi:10.1016/j.jvs.2022.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。